Research
Hormonal
Tirzepatid is being studied for its safety and efficacy as a treatment for obesity.
Practitioners should consider Tirzepatid as a potential treatment option for obesity.
StrongSupportsmedium confidence
Jastreboff und Kollegium wollten in diesem Zuge mehr über Sicherheit und Wirksamkeit des Glukose-abhängigen insulinotropen Polypeptid/Glucagon-like Peptide 1 (GIP/GLP-1)-Agonisten Tirzepatid erfahren.
Why this rating
The study is a Phase-III trial, indicating a high level of evidence.
Source
Adipositas: Tirzepatid sicher und wirksam?
DMW - Deutsche Medizinische Wochenschrift · 2022
DOI 10.1055/a-1916-2653
other
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →